About:
Autonomous Therapeutics is developing pan-variant RNA medicines to end viral pandemics. Following COVID-19, one question of paramount importance to Autonomous is how we can ensure that we are better prepared for the next pandemic. Autonomous’ solution is to create a collective antiviral tool kit that uses broad-spectrum antivirals to have therapies in advance of another pandemic. The idea is that the antiviral would provide resistance-proof protection against any Coronavirus or Influenza strain, including future viral mutants that could evade vaccines. Autonomous’ rationale is to engineer antivirals out of conserved genetic elements that are shared across a viral genus. The next milestone for Autonomous is to demonstrate the safety and efficacy of their antivirals in clinical trials.